榮昌生物(688331.SH):2023年度擬向銀行及其他金融機構申請不超50億元綜合授信額度
格隆匯3月29日丨榮昌生物(688331.SH)公佈,根據公司經營需求及財務狀況,公司2023年度擬向銀行及其他金融機構申請總額不超過50億元人民幣(或等值外幣)的綜合授信額度,授信類型包括但不限於短期流動資金貸款、項目貸款、中長期借款、銀行承兑匯票、保函等,具體的授信業務品種、授信期限及額度以公司與相關金融機構最終簽訂的合同或協議為準。
上述授信額度不等於公司的實際融資金額,具體融資金額在綜合授信額度內,並以銀行等金融機構與公司實際發生的融資金額為準,具體融資金額及品種將視公司業務發展的實際需求來合理確定。授信期限內,授信額度由公司及全資子公司共同滾動使用,可以循環使用。授信額度有效期自本次董事會審議通過之日起至下一年度審議年度授信額度的董事會決議通過之日止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.